Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

JPMorgan Active Growth ETF (NY:JGRO)

92.98 -1.71 (-1.81%)
Official Closing Price Updated: 8:00 PM EST, Dec 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about JPMorgan Active Growth ETF

< Previous 1 2 3 Next >
Eli Lilly To Set Up $5B Facility In Virginia – More Details Inside ↗
Via Stocktwits
Eli Lilly, Novo Nordisk Preparing To Introduce Obesity Pills Next Year In The US: Report ↗
Via Stocktwits
US FTC Probes Amazon, Google Over Search Advertising Practices: Report ↗
Via Stocktwits
AbbVie Stock Touches Record High After Company Dismisses Generic Competition For Rinvoq Till 2037: Wells Fargo Terms It A ‘Big Win’ ↗
Via Stocktwits
GE Vernova To Sell Proficy Software Unit To TPG For $600M ↗
Via Stocktwits
News headline image
Hims & Hers Stock Rises After Company Launches Treatment Plans For Low Testosterone ↗
According to Stocktwits data, retail chatter around HIMS stock increased by 21% over the last 24 hours and by approximately 533% over the last 30 days as of the early hours on Wednesday. 
Via Stocktwits
News headline image
Eli Lilly Launches AI, Machine Learning Platform Called TuneLab For Biotech Companies ↗
The platform will provide biotech companies access to drug discovery models trained on years of Lilly's research data, the company stated. 
Via Stocktwits
Topics Artificial Intelligence
This Pharma Giant Is Set To Invest $2B To Expand Manufacturing In North Carolina, And It Just Received A Price Target Hike From Citi: Do You Own It? ↗
Via Stocktwits
Apple Plans Tabletop Robot, Among Other AI Products, Says Report ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
Eli Lilly To Hike Mounjaro Prices By A Whopping 170% In UK: Retail Expects Stock To See Smooth Rally Till $720 ↗
According to the Financial Times, the price for a month’s supply of the highest doses of the drug will rise from £122 to £330, an increase of 170%. 
Via Stocktwits
Topics Government World Trade
News headline image
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week ↗
The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy. 
Via Stocktwits
News headline image
Texas Sues Eli Lilly Over Bribery Allegations: Retail Focuses On Company’s Upbeat Performance ↗
Texas Attorney General Ken Pax­ton alleged that Lilly offered illegal incentives to medical providers in Texas designed to steer providers toward prescribing Lilly’s drugs. 
Via Stocktwits
Topics Fraud Law Enforcement Lawsuit
Gilead Stock Showered With Upgrades, Price Target Hikes After Upbeat Q2, Guidance Lift: Retail’s Turned Exuberant ↗
Via Stocktwits
US Regulator Grants Exemption For Zoox Vehicles To Be On Road Without Compliance With Federal Standards ↗
Via Stocktwits
News headline image
BMO Capital Has An Important Take On Gilead Sciences, Retail’s Keeping The Optimism Alive ↗
The Supreme Court's Braidwood decision only concretized the power of the Department of Health and Human Services to decide what is necessary preventative care, rather than outright protecting... 
Via Stocktwits
News headline image
Gilead Gets Analyst Thumbs Up On Market Potential Of HIV-Prevention Injection, But Retail’s Not Ready To Cheer Yet ↗
Needham has a $133 price target on the stock, representing an upside of about 17.5% to the stock’s closing price on Thursday. 
Via Stocktwits
Topics Workforce
News headline image
Abbott Stock Slips On Disappointing Q3 Earnings Forecast: Retail Chatter Rises Over 200% In 24 Hours ↗
Abbott’s sales of continuous glucose monitors were $1.9 billion in the second quarter, marking a growth of 21.4% on a reported basis, the company said. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
AbbVie Enters Licensing Agreement For IGI Therapeutics’ Experimental Oncology Drug: Retail Cheers ↗
Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China. 
Via Stocktwits
Topics Product Recall
News headline image
Intuitive Surgical Gets FDA Clearance For Advanced Energy Surgical Instrument: Retail Sentiment Improves ↗
Vessel Sealer Curved is a fully wristed, advanced bipolar electrosurgical instrument designed to seal, cut, grasp, and dissect tissue for use with Intuitive’s da Vinci surgical systems. 
Via Stocktwits
News headline image
Crumly Loads Up on 110,675 SDVY Shares in Q2 Filing ↗
Crumly & Associates Inc. reported purchasing 110,675 shares of SDVY valued at $3.81 million in Q2 2025, according to a July 2 SEC filing. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Gilead, Global Fund Enter Agreement To Supply HIV Prevention Drug To Low & Lower-Middle-Income Countries ↗
Under the agreement, Gilead will supply enough doses of its Lenacapavir drug to reach up to two million people over three years in countries supported by the Global Fund, at no profit to the company. 
Via Stocktwits
News headline image
Eli Lilly’s Alzheimer’s Drug Gets US FDA Label Update For More Gradual Dosing After Study Shows Reduced Side Effects ↗
The U.S. FDA approved Kisunla, an amyloid-targeting therapy, in July 2024 after a study showed that it significantly slowed cognitive and functional decline in Alzheimer’s patients who were less... 
Via Stocktwits
News headline image
Johnson & Johnson Submits Supplemental Drug Application To FDA For Schizophrenia Drug Caplyta ↗
J&J gained access to Caplyta by the acquisition of Intra-Cellular Therapies, Inc., which was completed in April. 
Via Stocktwits
Topics Government
News headline image
AbbVie To Acquire Capstan Therapeutics For Up To $2.1 Billion To Boost Immunology Portfolio As Humira Sales Drop: Stock Gains In Morning Trade ↗
The acquisition will include Capstan’s lead asset, called CPTX2309, in development for the treatment of B-cell-mediated autoimmune diseases. 
Via Stocktwits
Topics Intellectual Property
News headline image
Gilead Stock Rises On US Supreme Court Ruling In Favor Of Health Insurers Covering Preventive Care ↗
Jefferies termed the Supreme Court’s ruling an ‘incremental positive’ for Gilead that removes an overhang going into the launch for Yeztugo. 
Via Stocktwits
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.